Skip to main content
Erschienen in: Investigational New Drugs 5/2017

04.04.2017 | PRECLINICAL STUDIES

New doxorubicin nanocarriers based on cyclodextrins

verfasst von: Maurizio Viale, Valentina Giglio, Massimiliano Monticone, Irena Maric, Giovanni Lentini, Mattia Rocco, Graziella Vecchio

Erschienen in: Investigational New Drugs | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Summary

Polymeric nanoparticles and fibrin gels (FBGs) are attractive biomaterials for local delivery of a variety of biotherapeutic agents, from drugs to proteins. We combined these different drug delivery approaches by preparing nanoparticle-loaded FBGs characterized by their intrinsic features of drug delivery rate and antiproliferative/apoptotic activities. Inclusion complexes of doxorubicin (DOXO) with oligomeric β-cyclodextrins (oCyD) functionalized with different functional groups were studied. These nanocarriers were able to interact with FBGs as shown by a decreased release rate of DOXO. One of these complexes, oCyDNH2/DOXO, demonstrated good antiproliferative and apoptotic activity in vitro, reflecting a higher drug uptake by cells. As hypothesized, the nanocarrier/FBG complexes showed a lower drug release rate than similar FBGs loaded with the corresponding non-functionalized oCyD/DOXO. Taken together, our results provide experimental evidence that oCyDNH2/DOXO complexes may be useful components in enhanced FBGs and further build support for the great promise these complex molecules hold for clinical use in localized anticancer therapy of inoperable or surgically removable tumors of different histological origin.
Literatur
1.
Zurück zum Zitat Gidwani B, Vyas A (2014) Synthesis, characterization and application of epichlorohydrin-β-cyclodextrin polymer. Colloids Surf B 114:130–137CrossRef Gidwani B, Vyas A (2014) Synthesis, characterization and application of epichlorohydrin-β-cyclodextrin polymer. Colloids Surf B 114:130–137CrossRef
2.
Zurück zum Zitat Hu C-MJ, Fang RH, Luk BT, Zhang L (2014) Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies. Nano 6:65–75 Hu C-MJ, Fang RH, Luk BT, Zhang L (2014) Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies. Nano 6:65–75
3.
Zurück zum Zitat Ruiz-Esparza GU, Wu S, Segura-Ibarra V, Cara FE, Evans KW, Milosevic M, Ziemys A, Kojic M, Meric-Bernstam F, Ferrari M, Blanco E (2014) Polymer nanoparticles encased in a Cyclodextrin Complex Shell for potential site- and sequence-specific drug release. Adv Funct Mater 24:4753–4761CrossRef Ruiz-Esparza GU, Wu S, Segura-Ibarra V, Cara FE, Evans KW, Milosevic M, Ziemys A, Kojic M, Meric-Bernstam F, Ferrari M, Blanco E (2014) Polymer nanoparticles encased in a Cyclodextrin Complex Shell for potential site- and sequence-specific drug release. Adv Funct Mater 24:4753–4761CrossRef
4.
Zurück zum Zitat Oliveri V, D’Agata R, Giglio V, Spoto G, Vecchio G (2013) Cyclodextrin-functionalised gold nanoparticles via streptavidin: a supramolecular approach. Supramol Chem 25:465–473CrossRef Oliveri V, D’Agata R, Giglio V, Spoto G, Vecchio G (2013) Cyclodextrin-functionalised gold nanoparticles via streptavidin: a supramolecular approach. Supramol Chem 25:465–473CrossRef
5.
Zurück zum Zitat Swaminathan S, Cavalli R, Trotta F (2016) Cyclodextrin-based nanosponges: a versatile platform for cancer nanotherapuetics development. WIREs Nanomed Nanobiotechnol 8:579–601CrossRef Swaminathan S, Cavalli R, Trotta F (2016) Cyclodextrin-based nanosponges: a versatile platform for cancer nanotherapuetics development. WIREs Nanomed Nanobiotechnol 8:579–601CrossRef
7.
Zurück zum Zitat Anand R, Malanga M, Manet I, Manoli F, Tuza K, Aykac A, Ladaviere C, Fenyvesi E, Vargas-Berenguel A, Gref R, Monti S (2013) Citric acid-γ-cyclodextrin crosslinked oligomers as carriers for doxorubicin delivery. Photochem Photobiol Sci 12:1841–1854CrossRef Anand R, Malanga M, Manet I, Manoli F, Tuza K, Aykac A, Ladaviere C, Fenyvesi E, Vargas-Berenguel A, Gref R, Monti S (2013) Citric acid-γ-cyclodextrin crosslinked oligomers as carriers for doxorubicin delivery. Photochem Photobiol Sci 12:1841–1854CrossRef
8.
Zurück zum Zitat Folch-Cano C, Yazdani-Pedram M, Olea-Azar C (2014) Inclusion and functionalization of polymers with cyclodextrins: current applications and future prospects. Molecules 19:14066–14079CrossRef Folch-Cano C, Yazdani-Pedram M, Olea-Azar C (2014) Inclusion and functionalization of polymers with cyclodextrins: current applications and future prospects. Molecules 19:14066–14079CrossRef
9.
Zurück zum Zitat Heidel JD, Schluep T (2012) Cyclodextrin-containing polymers: versatile platforms of drug delivery materials. J Drug Deliv ID 262731:1–17 Heidel JD, Schluep T (2012) Cyclodextrin-containing polymers: versatile platforms of drug delivery materials. J Drug Deliv ID 262731:1–17
10.
Zurück zum Zitat Avnesh S, Thakor MD, Sanjiv S, Gambhir MD (2013) Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J Clin 63:395–418CrossRef Avnesh S, Thakor MD, Sanjiv S, Gambhir MD (2013) Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J Clin 63:395–418CrossRef
11.
Zurück zum Zitat Bartlett DW, Davis ME (2007) Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem 18:456–468CrossRef Bartlett DW, Davis ME (2007) Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem 18:456–468CrossRef
12.
Zurück zum Zitat Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067–1670CrossRef Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067–1670CrossRef
13.
Zurück zum Zitat Giglio V, Viale M, Monticone M, Aura AM, Spoto G, Natile G, Intini FP, Vecchio G (2016) Cyclodextrin polymers as carries for the platinum-based anticancer agent LA-12. RSC Adv 6:12461–12466CrossRef Giglio V, Viale M, Monticone M, Aura AM, Spoto G, Natile G, Intini FP, Vecchio G (2016) Cyclodextrin polymers as carries for the platinum-based anticancer agent LA-12. RSC Adv 6:12461–12466CrossRef
14.
Zurück zum Zitat Kanwar JR, Long BM, Kanwar RK (2011) The use of cyclodextrins nanoparticles for oral delivery. Curr Med Chem 18:2079–2085CrossRef Kanwar JR, Long BM, Kanwar RK (2011) The use of cyclodextrins nanoparticles for oral delivery. Curr Med Chem 18:2079–2085CrossRef
15.
Zurück zum Zitat Longmire M, Choyke PL, Kobayashi H (2008) Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (London) 3:703–717CrossRef Longmire M, Choyke PL, Kobayashi H (2008) Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (London) 3:703–717CrossRef
16.
Zurück zum Zitat Dal Ben D, Palumbo M, Zagotto G, Capranico G, Moro S (2007) DNA topoisomerase II structures and anthracyclines activity: insights into ternary complex formation. Curr Pharm Des 13:2766–2780CrossRef Dal Ben D, Palumbo M, Zagotto G, Capranico G, Moro S (2007) DNA topoisomerase II structures and anthracyclines activity: insights into ternary complex formation. Curr Pharm Des 13:2766–2780CrossRef
17.
Zurück zum Zitat Grosse PY, Bressolle F, Pinguet F (1997) Methyl-beta-cyclodextrin in HL-60 parental and multidrug-resistant cancer cell lines: effect on the cytotoxic activity and intracellular accumulation of doxorubicin. Cancer Chemother Pharmacol 40:489–494CrossRef Grosse PY, Bressolle F, Pinguet F (1997) Methyl-beta-cyclodextrin in HL-60 parental and multidrug-resistant cancer cell lines: effect on the cytotoxic activity and intracellular accumulation of doxorubicin. Cancer Chemother Pharmacol 40:489–494CrossRef
18.
Zurück zum Zitat Al-Omar A, Abdou S, De Robertis L, Marsura A, Finance C (1999) Complexation study and anticellular activity enhancement by doxorubicin-cyclodextrin complexes on a multidrug-resistant adenocarcinoma cell line. Bioorg Med Chem Lett 9:1115–1120CrossRef Al-Omar A, Abdou S, De Robertis L, Marsura A, Finance C (1999) Complexation study and anticellular activity enhancement by doxorubicin-cyclodextrin complexes on a multidrug-resistant adenocarcinoma cell line. Bioorg Med Chem Lett 9:1115–1120CrossRef
19.
Zurück zum Zitat Gil ES, Li J, Xiao H, Lowe TL (2009) Quaternary ammonium -cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier. Biomacromolecules 10:505–516CrossRef Gil ES, Li J, Xiao H, Lowe TL (2009) Quaternary ammonium -cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier. Biomacromolecules 10:505–516CrossRef
20.
Zurück zum Zitat Bozzuto G, Molinari A (2015) Liposomes as nanomedical devices. Int J Nanomedicine 10:975–999CrossRef Bozzuto G, Molinari A (2015) Liposomes as nanomedical devices. Int J Nanomedicine 10:975–999CrossRef
21.
Zurück zum Zitat Jhaveri MS, Rait AS, Chung K-N, Trepel JB, Chang EH (2004) Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther 3:1505–1512PubMed Jhaveri MS, Rait AS, Chung K-N, Trepel JB, Chang EH (2004) Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther 3:1505–1512PubMed
22.
Zurück zum Zitat Giglio V, Sgarlata C, Vecchio G (2015) Novel amino-cyclodextrin cross-linked oligomer as efficient carrier for anionic drugs: a spectroscopicand nanocalorimetric investigation. RSC Adv 5:16664–16671CrossRef Giglio V, Sgarlata C, Vecchio G (2015) Novel amino-cyclodextrin cross-linked oligomer as efficient carrier for anionic drugs: a spectroscopicand nanocalorimetric investigation. RSC Adv 5:16664–16671CrossRef
23.
Zurück zum Zitat Dinges HP, Redl H, Thurnher M, Schiesser A, Schlag G (1986) Morphometric studies on wound healing after systemic administration of Adriamycin and local application of fibrin sealant: application of a new wound healing model using spongiosa implants. Pathol Res Pract 181:746–754CrossRef Dinges HP, Redl H, Thurnher M, Schiesser A, Schlag G (1986) Morphometric studies on wound healing after systemic administration of Adriamycin and local application of fibrin sealant: application of a new wound healing model using spongiosa implants. Pathol Res Pract 181:746–754CrossRef
24.
Zurück zum Zitat Kitazawa H, Sato H, Adachi I, Masuko Y, Horikoshi I (1997) Microdialysis assessment of fibrin glue containing sodium alginate for local delivery of doxorubicin in tumor bearing rats. Biol Pharm Bull 20:278–281CrossRef Kitazawa H, Sato H, Adachi I, Masuko Y, Horikoshi I (1997) Microdialysis assessment of fibrin glue containing sodium alginate for local delivery of doxorubicin in tumor bearing rats. Biol Pharm Bull 20:278–281CrossRef
25.
Zurück zum Zitat Yoshida H, Yamaoka Y, Shinoyama M, Kamiya A (2000) Novel drug delivery system using autologous fibrin glue-release properties of anti-cancer drugs. Biol Pharm Bull 23:371–374CrossRef Yoshida H, Yamaoka Y, Shinoyama M, Kamiya A (2000) Novel drug delivery system using autologous fibrin glue-release properties of anti-cancer drugs. Biol Pharm Bull 23:371–374CrossRef
26.
Zurück zum Zitat Viale M, Rossi M, Russo E, Cilli M, Aprile A, Profumo A, Santi P, Fenoglio C, Cafaggi S, Rocco M (2015) Fibrin gels loaded with cisplatin and cisplatin-hyaluronate complexes tested in a subcutaneous human melanoma model. Invest New Drugs 33:1151–1116CrossRef Viale M, Rossi M, Russo E, Cilli M, Aprile A, Profumo A, Santi P, Fenoglio C, Cafaggi S, Rocco M (2015) Fibrin gels loaded with cisplatin and cisplatin-hyaluronate complexes tested in a subcutaneous human melanoma model. Invest New Drugs 33:1151–1116CrossRef
27.
Zurück zum Zitat Novi M, Ottone M, Dell’Erba C, Barbieri F, Chiavarina B, Maccagno M, Viale M (2004) 1,4-Bis(1-naphtyl)-2,3-dinitro-1,3-butadiene a novel anticancer compound effective against tumor cell lines characterized by different mechanisms of resistance. Oncol Rep 12:91–96PubMed Novi M, Ottone M, Dell’Erba C, Barbieri F, Chiavarina B, Maccagno M, Viale M (2004) 1,4-Bis(1-naphtyl)-2,3-dinitro-1,3-butadiene a novel anticancer compound effective against tumor cell lines characterized by different mechanisms of resistance. Oncol Rep 12:91–96PubMed
28.
Zurück zum Zitat Dell’Erba C, Chiavarina B, Fenoglio C, Petrillo G, Cordazzo C, Boncompagni E, Spinelli D, Ognio E, Aiello C, Mariggiò MA, Viale M (2005) Inhibition of cell proliferation, cytotoxicity and induction of apoptosis of 1, 4-bis (1-naphthyl)-2, 3-dinitro-1, 3-butadiene in gastrointestinal tumor cell lines and preliminary evaluation of its toxicity in vivo. Pharmacol Res 52:271–282CrossRef Dell’Erba C, Chiavarina B, Fenoglio C, Petrillo G, Cordazzo C, Boncompagni E, Spinelli D, Ognio E, Aiello C, Mariggiò MA, Viale M (2005) Inhibition of cell proliferation, cytotoxicity and induction of apoptosis of 1, 4-bis (1-naphthyl)-2, 3-dinitro-1, 3-butadiene in gastrointestinal tumor cell lines and preliminary evaluation of its toxicity in vivo. Pharmacol Res 52:271–282CrossRef
29.
Zurück zum Zitat Etrych T, Chytil P, Jelínková M, Ríhová B, Ulbrich K (2002) Synthesis of HPMA copolymers containing doxorubicin bound via a hydrazone linkage. Effect of spacer on drug release and in vitro cytotoxicity. Macromol Biosci 2:43–52CrossRef Etrych T, Chytil P, Jelínková M, Ríhová B, Ulbrich K (2002) Synthesis of HPMA copolymers containing doxorubicin bound via a hydrazone linkage. Effect of spacer on drug release and in vitro cytotoxicity. Macromol Biosci 2:43–52CrossRef
Metadaten
Titel
New doxorubicin nanocarriers based on cyclodextrins
verfasst von
Maurizio Viale
Valentina Giglio
Massimiliano Monticone
Irena Maric
Giovanni Lentini
Mattia Rocco
Graziella Vecchio
Publikationsdatum
04.04.2017
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 5/2017
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-017-0461-0

Weitere Artikel der Ausgabe 5/2017

Investigational New Drugs 5/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.